How health care stakeholders, such as patients, physicians and payers consider the value of a health treatment can differ greatly, and those different viewpoints can have a tremendous impact on personalized care. During a Nov. 15 panel session at the 13th Annual Personalized Medicine Conference, hosted by the Personalized Medicine Coalition, in Boston, Massachusetts, NPC Executive Vice President and Chief Science Officer Robert W. Dubois, MD, PhD, will explore the reasons behind some of those viewpoints and how we can take those into account when conducting value assessments.
Value assessment frameworks are growing in use as a way for stakeholders to measure the value of a health care intervention. But it’s challenging for frameworks to incorporate all of the preferences that matter to stakeholders in one assessment. Treatment preferences, such as survival, quality of life and treatment requirements, differ not only by stakeholder, but by the type of condition as well. Depending on the condition, out of pocket costs, for example, may be an important consideration that is outweighed by survivability; this finding is part of a broader NPC-led study that Dr. Dubois will share as part of the panel discussion, “Precision Valuation: A Discussion of How Value Assessment Frameworks Can Account for Personalized Medicine.”
Dr. Dubois will be joined on the panel, which kicks off at 3:15 pm, by:
- Dane J. Dickson, M.D., CEO, Cure-One (formerly MED-C); Director, Precision Medicine Policy and Registries, Knight Cancer Center at OHSU
- Steven Pearson, M.D., M.Sc., Founder and President, Institute for Clinical and Economic Review (ICER)
- Andrea Ferris, M.B.A., President, Chairman of the Board, LUNGevity Foundation
And don’t miss a fireside chat with Joshua Ofman, MD, MSHS, Senior Vice President of Global Value, Access & Policy, Amgen, and 2017 Chairman of NPC’s Board of Directors. Dr. Ofman will speak on “A Model for Risk-Sharing Agreements Between Payers and the Pharmaceutical Industry” on Nov. 15 at 9:45 a.m., where he will discuss the logic and implications of risk-sharing agreements with CNBC reporter Meg Tirrell.